Last edition
News about "Biogen"
Biogen licences Vanqua Bio's immune-disorder drug in deal worth up to USD 1.06 billion
Biogen has entered into an agreement with Vanqua Bio to acquire global rights to an experimental oral therapy for immune-related disorders, in a deal valued at up to USD 1.06 billion.
Biogen | 27/10/2025 | By Darshana
US FDA Declines Approval for Biogen's Higher-Dose Spinraza in SMA
The decision was relayed via a ‘complete response letter’ to Biogen, which clarified there were no issues with the clinical data behind the new high-dose regimen. Biogen says it will resubmit the application promptly, drawing on information that is already at hand.
Biogen | 24/09/2025 | By Darshana
Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars
Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.
Biogen | 18/07/2025 | By Dineshwori | 136
Biogen and Stoke Therapeutics to Develop and Commercialize Zorevunersen
Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome.
Biogen | 20/02/2025 | By Aishwarya | 221
Royalty Pharma Signs R&D Funding Agreement with Biogen
Litifilimab is currently in Phase 3 trials for both SLE and CLE with results expected between 2026 and 2027.
Biogen | 13/02/2025 | By Aishwarya | 220
ALS drug by Biogen and Ionis Pharmaceuticals fails in trials
Biogen and Ionis Pharmaceuticals were hoping to be the first to find a cure for ALS. That dream has now fizzled out with the companies calling it quits after receiving disappointing results from a phase 1 clinical trial.
Biogen | 27/04/2022 | By Sudeep Soparkar | 646
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy